Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Real-life experiences with goal-directed prohemostatic therapy with fibrinogen concentrate, prothrombin complex concentrate, and recombinant factor VIIa: a retrospective study of 287 consecutive patients

Research output: Contribution to journalJournal articlepeer-review

  1. Bone mass density in lean and overweight women with polycystic ovary syndrome

    Research output: Contribution to journalJournal articlepeer-review

  2. Managing patients on direct factor Xa inhibitors with rapid thrombelastography

    Research output: Contribution to journalJournal articlepeer-review

  1. An explorative metabolomic analysis of the endothelium in pulmonary hypertension

    Research output: Contribution to journalJournal articlepeer-review

  2. Intervening on the storage time of RBC units and its effects on adverse recipient outcomes using real-world data

    Research output: Contribution to journalJournal articlepeer-review

  3. Exploratory Investigation of the Plasma Proteome Associated with the Endotheliopathy of Trauma

    Research output: Contribution to journalJournal articlepeer-review

View graph of relations

The Danish Capital Region Blood Bank operates a 24/7 on-call service staffed with physicians specialized in hemostatic management to guide clinicians in hemostatic resuscitation, including administration of prohemostatic therapy (PHT). The outcome of patients who receive PHT as part of hemostatic resuscitation remains unanswered. The objective of this study was therefore to investigate clinical outcome of patients receiving PHT managed by the on-call service. We identified 287 patients who received PHT during 2015-16, of which 161 (59%) received fibrinogen concentrate (FC), 111 (39%) received prothrombin complex concentrate (PCC), and 15 (5%) received recombinant factor VIIa (rFVIIa) as the first product. Patients were critically ill with a 30-day mortality of 31%. Among FC recipients, cardiothoracic admission, non-trauma, and antithrombotics predicted survival. FC recipients had lower platelet count and thrombelastography clot strengths than the other PHT groups and within the group, these factors predicted mortality. The symptomatic thromboembolic event (TE) rate at 30 days was 5%. For PCC recipients, vitamin K antagonists predicted survival, while rivaroxaban predicted mortality. TE rate was 2%. We did not identify factors associated with survival in the small group of rFVIIa recipients. TE rate was 13%. In summary, trauma and coagulopathy predicted mortality in patients who received FC and our data suggest that optimization of PHT algorithms may be possible. Outcome of patients who received PCC was comparable to results reported elsewhere and its use may be safe in a setting as reported here. Recombinant FVIIa was rarely used but had the highest incidence of arterial thromboembolism.

Original languageEnglish
JournalScandinavian Journal of Clinical and Laboratory Investigation
Volume82
Issue number2
Pages (from-to)156-161
Number of pages6
ISSN0036-5513
DOIs
Publication statusPublished - Apr 2022

    Research areas

  • Factor VIIa, fibrinogen, hemostasis, prothrombin complex concentrates, thrombelastography

ID: 74724211